Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy of 2 Fixed Doses (50 and 100 mg/Day) of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder

NCT01432457 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01432457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01432457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy of 2 Fixed Doses (50 and 100 mg/Day) of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2011
Completion date
August 31, 2012
Enrollment
924 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder